Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Ahead of print articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 25, Number 7—July 2019
Letter

Racial/Ethnic Disparities in Antimicrobial Drug Use, United States, 2014–2015

Suggested citation for this article

To the Editor: We read with interest the article by Olesen and Grad (1), which reported that, in the United States during 2014–2015, the rate of antimicrobial drug use by white persons was twice that of persons of other races. The authors did not relate this finding to previous reports of ≈2 times lower incidence of sepsis (2) and ≈1.5 times lower incidence of death from infectious diseases (3) in white persons in the United States.

A national study of community antibacterial dispensing in relation to ethnicity in New Zealand (4) found that the dispensing rates were highest in Pacific people and Maori, consistent with their higher incidence of infectious diseases. However, the ethnic disparities in dispensing rates were substantially less than the ethnic disparities in the incidence of some infections. For example, even though the incidence of hospitalization for rheumatic fever was 63 times higher for Pacific people and 27 times higher for Maori than for persons of all other ethnicities combined, the annual dispensing rates of penicillins for Pacific people and Maori were <1.5 times higher than in other ethnicities.

Olesen and Grad suggest that ethnic disparities in antimicrobial drug use will lead to disparities in the prevalence of colonization (and disease) by antimicrobial-resistant bacteria. The New Zealand study found that dispensing rates of topical antimicrobial agents (predominantly fusidic acid) for Pacific and Maori children were approximately twice those for children of other ethnicities and suggested that these high dispensing rates might have contributed to the higher proportion of staphylococcal infections caused by methicillin-resistant (and fusidic acid–resistant) Staphylococcus aureus in Pacific people and Maori (5). We suggest that improved understanding of ethnic disparities in the incidence of infectious diseases and in the level of consumption of antimicrobial agents might usefully inform antimicrobial stewardship targets and strategies.

Top

Mark ThomasComments to Author , Naomi Whyler, Andrew Tomlin, and Murray Tilyard

Author affiliations: University of Auckland, Auckland, New Zealand (M. Thomas); Auckland City Hospital, Auckland (M. Thomas, N. Whyler); Best Practice Advocacy Centre, Dunedin, New Zealand (A. Tomlin, M. Tilyard)

Top

References

  1. Olesen  SW, Grad  YH. Racial/ethnic disparities in antimicrobial drug use, United States, 2014–2015. Emerg Infect Dis. 2018;24:21268. DOIPubMed
  2. Martin  GS, Mannino  DM, Eaton  S, Moss  M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:154654. DOIPubMed
  3. Richardus  JH, Kunst  AE. Black-white differences in infectious disease mortality in the United States. Am J Public Health. 2001;91:12513. DOIPubMed
  4. Whyler  N, Tomlin  A, Tilyard  M, Thomas  M. Ethnic disparities in community antibacterial dispensing in New Zealand, 2015. N Z Med J. 2018;131:5060.PubMed
  5. Williamson  DA, Monecke  S, Heffernan  H, Ritchie  SR, Roberts  SA, Upton  A, et al. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale. Clin Infect Dis. 2014;59:14514. DOIPubMed

Top

Suggested citation for this article: Thomas M, Whyler N, Tomlin A, Tilyard M. Racial/ethnic disparities in antimicrobial drug use, United States, 2014–2015. Emerg Infect Dis. 2019 Jul [date cited]. https://doi.org/10.3201/eid2507.181775

DOI: 10.3201/eid2507.181775

Original Publication Date: 5/15/2019

Related Links

Top

Table of Contents – Volume 25, Number 7—July 2019

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Mark Thomas, Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Rd, Grafton, Auckland 1023, New Zealand

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: May 15, 2019
Page updated: May 15, 2019
Page reviewed: May 15, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external